Fredun Pharmaceuticals Limited, listed on the BSE under the code 539730, has announced a strong financial performance for the quarter and year ended March 31, 2025, underscoring its evolving strategy and growing presence across diversified healthcare verticals. The company's expansion into veterinary health, international markets, and diagnostics, along with robust financial results, signals a transformative year for the organisation.

Q4 FY25 Performance
For the fourth quarter of FY25, Fredun Pharma recorded a Total Income of Rs. 167.4 crore, up from Rs. 118.0 crore in Q4 FY24, marking a 41.8% year-on-year (YoY) growth. The EBITDA for the quarter stood at Rs. 17.4 crore, compared to Rs. 11.2 crore in the same period last year, representing a 56.2% YoY rise. The EBITDA margin was 10.4%, improving from 9.5% a year ago. Profit After Tax (PAT) also saw an impressive rise, reaching Rs. 7.1 crore, compared to Rs. 5.1 crore in Q4FY24—a growth of 39.7% YoY.

FY25 Annual Performance
On an annual basis, the company’s Total Income rose by 30.7% YoY, reaching Rs. 456.3 crore as compared to Rs. 349.1 crore in FY24. EBITDA grew by 41.6%, rising from Rs. 38.9 crore to Rs. 55.1 crore. The company’s EBITDA margin improved from 11.1% in FY24 to 12.1% in FY25. PAT reached Rs. 20.8 crore, a 33.2% YoY increase from the previous year’s Rs. 15.6 crore. This reflects consistent performance and improved operational efficiency.

New Business Segments and Product Launches
One of the most significant strategic moves by Fredun Pharma this year was its entry into the Large Animal Veterinary segment. The company launched the FREOSSI Large Animals brand with products such as Freossi Tone+ and Freossi Power, developed by veterinary professionals. These formulations are specifically designed to enhance lactation, improve milk quality, and reduce joint stiffness in large animals such as cattle. This new vertical not only diversifies the company’s portfolio but also positions it as a holistic animal health provider.

International Foray with Freossi Petcare in Sri Lanka
Expanding its reach globally, Fredun Pharma launched its Freossi Petcare division in Sri Lanka. The launch included nine premium-quality products, including supplements and grooming items, with a pipeline of over 20 additional offerings planned. The event was inaugurated by leading veterinary professionals, marking a significant milestone in Fredun's efforts to provide scientifically developed pet care solutions. This international launch underscores the company’s commitment to global pet health markets.

Securing Government Contracts
Fredun Pharma also secured a substantial tender from Tamil Nadu Medical Services Corporation (TNMSC) for the supply of generic medicines, valued between Rs. 150–180 million. This not only boosts the company’s revenue but also reinforces its trust and reliability in the public healthcare system.

Order Book and Operational Strength
The company’s order book reached Rs. 213 crore, the highest ever in its operational history. This robust order pipeline provides clear revenue visibility and reflects strong customer demand across product segments.

Strategic Commentary by Management
Mr. Fredun Medhora, Managing Director, stated that FY25 was a transformative year, with significant milestones achieved across key focus areas. The company expanded into non-pharma verticals, and initiatives like FREDNA VET DIAGNOSTICS, functional foods for pets, and the launch of Chuu Balm, were introduced. The Chuu Balm has already seen a strong market response, especially in tier 2 and tier 3 cities.

He added, “Our main emphasis moving forward will be on expanding our Non-Pharma business, which we believe will be a key growth and profitability driver. The introduction of new-age products is expected to contribute significantly to margin expansion and long-term value creation.”

Non-Pharma Business on the Rise
The company is making substantial progress in its Non-Pharma segment, especially with the development of functional foods for pets, diagnostics, and grooming products. With the opening of India’s first advanced pet diagnostic centre—FREDNA VET DIAGNOSTICS—Fredun has strengthened its foothold in a niche but rapidly growing sector of pet healthcare.

Product Diversification and Export Strategy
Fredun Pharma has a diverse portfolio that includes antihypertensives, antidiabetic drugs, ARVs (antiretroviral drugs), narcotics, and herbal/nutraceutical supplements. In addition to its strong domestic presence, Fredun continues to export to Africa, Southeast Asia, CIS countries, and Latin America, establishing itself as a global player in pharmaceuticals and healthcare.

Forward Outlook
With a strong balance sheet, healthy margins, and a focused strategy, Fredun Pharmaceuticals is well-positioned to leverage future growth opportunities. The company expects its Non-Pharma business to drive profitability, while continuing to strengthen its core pharmaceutical manufacturing and export base.

Disclaimer
Certain statements in this report are forward-looking and may differ materially due to market dynamics, regulatory factors, or economic changes.

The Upcoming IPOs in this week and coming weeks are Ganga Bath Fittings, Victory Electric Vehicles International, Wagons Learning.

The Current active IPO are 3B Films, N R Vandana Tex Industries, Scoda Tubes, Neptune Petrochemicals.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.